U.S. health regulators announced on Monday that popular weight loss and diabetes drugs, including Ozempic and Wegovy, will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss. The FDA is requiring all GLP-1 makers to add a warning about the risk to their labeling. The agency said the warning applies to all GLP-1 medications, which are used to treat obesity, diabetes and several other medical conditions. The drug class includes a dozen injectable or pill-based drugs, including Zepbound and Mounjaro.
What the condition is
The eye condition is known as non-arteritic anterior ischemic optic neuropathy, or NAION, and it can cause significant vision loss. The FDA described it as a very rare condition in which a lack of blood flow to the optic nerve causes decreased vision or vision loss in an eye. It can lead to sudden and painless vision loss. The FDA said the condition has been reported with all GLP-1 drugs, though the underlying cause is not understood. FDA scientists were not able to identify a mechanism by which the drugs could increase the risk.
The FDA's findings
The FDA said semaglutide and other GLP-1 drugs on the market carry a potential increased risk of NAION. An FDA analysis of more than 125 clinical trials found the problem in roughly 6 of every 100,000 patients who took a GLP-1 drug for at least one year. The comparable rate for people taking a placebo or other glucose-lowering medications was less than 4 per 100,000. The agency also found reports of the problem in its electronic reporting system for drug injuries and side effects. FDA scientists began looking into the issue after a 2024 medical paper tied the condition to certain patients taking semaglutide, the active drug in Ozempic.
Guidance for patients
The FDA said symptoms include blurred vision, blind spots, distorted colors and other visual disturbances. Patients experiencing such problems should contact a health care professional immediately. Patients who have had a NAION event should talk with their health care professional about whether to continue or stop their GLP-1 medication. The FDA's statement says patients and caregivers should be aware of the potential increased risk.
Drugmaker responses
Spokespeople for Novo Nordisk and Eli Lilly said patient safety is their top priority. Eli Lilly said the FDA's safety communication applies to all medicines with GLP-1 RA activity and does not reference findings specific to Lilly medicines. The company said it was carefully evaluating the update.